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Essentials
• It is unknown if a male or female thrombotic family
history influences risk in female relatives.
• We assessed thrombotic risk in female relatives of male
and female patients with thrombosis.
• A hormonally related female thrombotic family history
further increases risk in female relatives.
• This information could be important in counseling
women on contraceptive options.
Click to hear Prof. Rosendaal’s perspective on venous
thrombosis: etiology, pathogenesis, and prognosis
Summary. Background: Women from thrombophilic fami-
lies have increased risk of venous thromboembolism
(VTE), which increases further during oral contraceptive
(COC) use and pregnancy-postpartum. Whether this addi-
tional risk differs between relatives of male and female
patients, or is different when that female patient had a
hormonally related VTE (during COC use/pregnancy), is
unknown. Methods: One thousand five female relatives of
consecutive patients with VTE from a family-based
cohort were retrospectively followed for incident VTE
from ages 15 to 50, first VTE, or study inclusion. Abso-
lute and relative VTE risks adjusted for factors of
patients (sex, age) and relatives (thrombophilia, COC use,
pregnancy) were estimated in relatives of female and male
patients and in relatives of female patients with and with-
out hormonally related VTE. Results: Absolute risk in
relatives of female (0.32 [95% confidence interval [CI]
0.23–0.43]) vs. male patients (0.39 [95% CI 0.28–0.53])
was comparable. However, the heterogeneity analysis of
risk estimates suggested that in relatives of female vs.
male patients, the contribution of pregnancy-postpartum
(hazard ratio [HR] 11.6 [95% CI 6.3–21.3] vs. HR6.6
[95% CI 2.8–15.2]) and, to a lesser extent, COC use
(HR3.6 [95% CI 1.8–7.1] vs. HR2.7 [95% CI 1.5–5.0]) to
the VTE risk differs. Absolute risk was significantly
higher in relatives of female patients with hormonally
related VTE (0.43 [95% CI 0.3–0.6]) vs. relatives of
female patients without hormonally related VTE (0.13
[95% CI 0.05–0.27]), HR3.28 [95% CI 1.5–7.9]). The
higher contribution of pregnancy-postpartum and COC
use to the VTE risk was mainly observed in relatives of
patients with hormonally related VTE. Conclusions:
These findings suggest that a family history from a female
patient, especially when VTE was hormonally related,
may further increase VTE risk in her female relatives.
This information could be important in counseling
women on contraceptive options.
Keywords: combined oral contraceptives; hereditary
thrombophilia; venous thromboembolism.
Introduction
There are many factors that contribute to the individual
baseline risk of venous thromboembolism (VTE). Heredi-
tary thrombophilia and first-degree family history are
both established independent risk factors [1–4]. The base-
line risk can be further increased by underlying conditions
like cancer and obesity, by exogenous risk factors such as
surgery and trauma, and, in women of reproductive age,
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by the use of combined oral contraceptives (COCs) and
the pregnancy-postpartum period [5]. Recent studies indi-
cate that exposure to hormone factors plays a decisive
role in the development of VTEs in women during the
reproductive age. Adjustment for reproductive risk factors
was reported to reduce risk of VTE in women of repro-
ductive age to half of that in men of the same age [6].
Previously, we studied the contribution of hormone
exposure (i.e., COC use and pregnancy-postpartum) to the
baseline risk of VTE in female relatives of patients with
VTE from families with mild (factor V [FV] Leiden and
prothrombin G20210A mutation) and severe hereditary
thrombophilia (antithrombin, protein C, and protein S
deficiency) [7–9]. It was shown that in female relatives of
reproductive age with thrombophilia the risk of VTE was
further increased during hormone exposure, of which the
impact was highest in women with severe thrombophilic
defects. Additionally, in these cohorts of female relatives of
patients with VTE, who per definition all had a positive
family history, those without thrombophilia also had a
higher risk of VTE during hormone exposure than reported
in the general population [7,8]. This is in line with publica-
tions indicating that family history is an independent risk
factor, regardless of other risk factors present [4]. It is
unknown whether this family-conferred risk is hormone or
sex specific: is a young woman at higher hormone-related
risk if her mother or sister had COC- or pregnancy-related
VTE than if her father or brother had thrombosis? This
would be relevant for counselling purposes.
In order to investigate this question, we have included in
the present study the first-degree female relatives of repro-
ductive age of consecutive patients with VTE and heredi-
tary thrombophilia from our thrombophilic family cohorts.
As all patients had experienced VTE, all female relatives
had an established positive family history of VTE. This
provided us with the unique opportunity to evaluate in
these female relatives the impact of a family history origi-
nating from a male or female patient and to investigate
whether a positive family history originating from a female
patient with a VTE during hormone exposure (during COC
use or pregnancy) has an additional impact on their risk
profile. For this purpose, we estimated absolute and rela-
tive risk of VTE in female relatives of male patients, of
female patients with hormonally related VTE, and of
female patients without hormonally related VTE.
Methods
Subjects
In the present family-based cohort study, female relatives
from consecutive patients (probands) with VTE were
included from five cohorts of thrombophilic families from
three university hospitals in the Netherlands, which were
described in detail elsewhere [1–3]. The first cohort was
single-center study of first-degree relatives of consecutive
probands with VTE and antithrombin, protein C, or
protein S deficiency. As the number of antithrombin defi-
cient probands was small, second-degree relatives with a
deficient parent were also identified. Enrollment took
place from 1999 to 2004. Three multicenter studies
included first-degree relatives of consecutive probands
with VTE or premature atherosclerosis (< 50 yrs) and
prothrombin-G20210A, high FVIII levels (150 IU dL1),
or hyperhomocysteinemia, respectively. The fifth study
was a multicenter study, which included first-degree rela-
tives of probands with VTE and an FV Leiden mutation.
These relatives were enrolled between 1995 and 1998 (FV
Leiden study) and 1998 and 2004 (prothrombin-
G20210A, hyperhomocysteinemia, and FVIII studies) at
three university hospitals in the Netherlands. Probands
were excluded to avoid bias, as they have experienced
VTE by definition. Relatives of probands with premature
atherosclerosis were not included in the present study. In
these cohorts, only hereditary thrombophilic defects were
taken into account; a high FVIII level and hyperhomo-
cysteinemia are not considered hereditary thrombophilic
defects (Fig. 1). Strategies applied for collection of infor-
mation on exposure to exogenous risk factors for VTE,
including contraceptive use and pregnancies (including
pregnancy losses), are described in detail in our previous
studies based on these cohorts [7–9]. Relatives were quer-
ied about exposure to VTE risk factors and VTE occur-
rence from time point of study inclusion back to the age
of 15. For the present cohort study, all data collected on
hormone exposure and risk factors present at time of
VTE of the probands were confirmed by review of the
probands’ medical files. All relatives had given informed
consent, and the original study cohorts were approved by
the institutional review boards of the three participating
Dutch hospitals (University Medical Centers of Gronin-
gen, Amsterdam, and Maastricht).
Person-years of exposure were counted from age 15
until 50 years, first VTE, or end of study. A minimum
age of 15 years was chosen because VTE occurrence
below this age is rare, and a maximum age of 50 years
was chosen as the end of fertile lifetime. The duration of
exposure to COCs (years of COC use) included actual use
including a 3-month exposure window after COC use was
discontinued. For pregnancy, including pregnancy losses,
exposure was defined as the gestation time plus 3-month
postpartum.
Diagnosis of VTE
VTE was considered established when diagnosed by com-
pression ultrasound or venography (deep vein thrombo-
sis), ventilation/perfusion lung scan, spiral computed
tomography scan, or pulmonary angiography (pulmonary
embolism) or when the patient had received full-dose
heparin and vitamin K antagonists for at least 3 months
without objective testing at a time when these techniques
© 2016 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.
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were not available. VTE was classified as ‘provoked’
when occurring up to 3 months after exposure to
exogenous risk factors, which included surgery, trauma,
immobilization for at least 7 days, COC use, pregnancy-
postpartum up to 3 months, and malignancy.
In the absence of these risk factors, VTE was defined
as ‘unprovoked.’ Superficial phlebitis was not considered
a thrombotic event [1–3].
Laboratory studies
FV Leiden and prothrombin-G20210A mutation were
demonstrated by polymerase chain reaction [10,11]. Pro-
tein S– and protein C–Ag levels were measured by ELISA
(DAKO, Glostrup, Denmark); protein C activity and
antithrombin levels (Chromogenix, M€olndal, Sweden)
were measured by chromogenic substrate assays.
Normal ranges were determined in healthy volunteers
without a (family) history of VTE, who were neither preg-
nant nor used COCs within 3 months before blood sam-
pling. Deficiency of antithrombin, protein S, and protein
C was defined by levels below the lower limit of their nor-
mal ranges.
In probands and symptomatic relatives, blood samples
were collected at least three months after VTE had
occurred. If they were still treated with vitamin K antago-
nists, samples were taken after temporary change of this
therapy to low molecular weight heparin for at least 2
weeks [1–3].
Statistical analysis
VTE risk estimation We estimated the overall absolute
risk of VTE in this cohort, as well as absolute VTE risk
in female relatives originating from a female vs. a male
patient (proband). The absolute risk was expressed as the
incidence rate (IR) per 100 person-years, with 95% confi-
dence intervals (CIs). Their person-years of exposure were
counted from age 15 until age 50, first VTE, or the end
of study (time of inclusion).
Relative risks were estimated using Cox regression
analysis. Testing proportionality (i.e., the proportional
hazard assumption) was part of the survival analysis.
The proportionality assumption was assessed by includ-
ing an interaction with event time in the model. To
account for time-varying exposures of COC use and
Affected probands














Female relatives with antithrombin,













Female relatives with incomplete
thrombophilic tests
Female relatives evaluable for analysis
Fig. 1. Recruitment of patients (probands) with venous thromboembolism (VTE) and first-degree female relatives.
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pregnancies, an extended Cox model (with time-varying
exposures) was used. In this multivariable model, hazard
ratios (HRs) of female vs. male proband, age of the pro-
band at time of first VTE (< 45 yrs vs. ≥ 45 yrs), COC
use vs. no use, pregnancy-postpartum vs. no pregnancy,
and presence of thrombophilia vs. no thrombophilia
were estimated. Possible effect modification (interactions)
of mild or severe thrombophilic defects on risk of COC
use and pregnancy-postpartum were also taken into
account.
Further, within the group of female relatives originat-
ing from a female proband, absolute and relative risk esti-
mations as described earlier were calculated for the
female relatives with a female proband with hormonally
related VTE (VTE during COC use or pregnancy-post-
partum) vs. female relatives with a female proband with-
out hormonally related VTE.
Because this is a family-based study, all relative risk
estimations were also adjusted for clustering within
families.
Continuous variables were expressed as mean values
and standard deviation (SD) or median values and range,
and categorical data as counts and percentages. A two-
sided P-value of < 0.05 indicated statistical significance.
Analyses were performed using SAS software, version 9.4
(SAS Institute., SAS Institute Inc., Cary, NC, USA).
Results
Clinical characteristics of probands and their female
relatives
The original cohorts consisted of 730 thrombophilic
patients (probands) with VTE. The flow chart, presented
in Fig. 1, displays the number of relatives of these
probands who could not be enrolled, which included non-
responders (no consent, geographical distance) and rela-
tives who were deceased. In total, 1230 relatives were
female. After excluding female relatives in whom inheri-
tance of the index defect could not be established, and
those who had incomplete thrombophilia testing, 1005
female relatives were available for analysis, originating
from 465 probands.
The upper part of Table 1 presents the characteristics
of the probands, divided into male and female probands
of whom the latter group is divided further into female
probands with or without a hormonally related VTE.
Characteristics of the probands in these three groups were
comparable with regard to hormone exposure (COC use
and pregnancy-postpartum), but probands with hormon-
ally related VTE had their first VTE at considerably
younger median age (i.e., 26.5 yrs) than female probands
without hormonally related VTE (44.0 yrs) and male pro-
bands (45.0 yrs).
The lower part of Table 1 presents the characteristics
of the 1005 female relatives of these probands, of whom
604 originated from a female proband and 401 from a
male proband. Of the 604 relatives of female probands,
394 originated from female probands with hormonally
related VTE and 206 from female probands without hor-
monally related VTE. For four relatives (who experienced
no VTE during follow-up), the female probands’ hor-
mone exposure at the time of VTE was unknown. The
characteristics did not differ strongly between relatives of
male proband and the two female proband groups. Deep
vein thrombosis (DVT) was diagnosed in the majority of
VTE cases, and the proportions of DVT, PE and other
VTE are comparable between relatives of male and
female probands. However, in the relatives with a VTE, a
median duration of COC use of 0.46 year up to time of
VTE was considerably shorter in relatives of female pro-
bands with hormonally related VTE than in female rela-
tives of female probands without hormonally related
VTE (5 yrs) and female relatives of male probands
(4 yrs).
VTE risk in female relatives of female vs. male probands
Follow-up in female relatives covered 24.195 person-years
with 84 VTEs, of which 82% was related to COC use or
pregnancy-postpartum. Crude absolute VTE risk was 0.35
(95% CI 0.28–0.43) per 100 person-years.
As presented in Table 2, the risk in relatives of female
(0.32, 95% CI 0.23–0.43) vs. male probands (0.39, 95%
CI 0.28–0.53) was comparable, but young age (< 45 yrs
at time of first VTE) of the proband, and presence of
thrombophilia, COC use, and pregnancy of the relative
were factors that significantly increased risk of VTE. In
the multivariable analysis, thrombophilia, COC use, and
pregnancy of relative, but not probands’ age, remained
independent risk factors.
However, the heterogeneity analysis of risk estimates
for relatives of male vs. female probands showed a sub-
stantially higher pregnancy-related risk of VTE (HR
11.6 [95% CI 6.3–21.3]) in relatives of female probands
than in relatives of male probands (HR 6.6 [95% CI
2.8–15.2]), although the formal test for interaction
between pregnancy and sex of proband was not signifi-
cant (P = 0.39). For COC use, the difference in
increased risk of VTE was less pronounced, that is, HR
3.6 (95% CI 1.8–7.1), in relatives of female probands vs.
HR 2.7 (95% CI 1.5–5.0) in relatives of male probands
(Table 3).
VTE risk in female relatives of female probands with or
without hormonally related VTE
When taking hormone exposure of the proband at the
time of VTE into account, the incidence rate (IR) of VTE
was significantly higher, that is, IR 0.43 (95% CI 0.31–
0.59) per 100 person-years in relatives of probands with
hormonally related VTE, than noted in relatives of female
© 2016 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis.
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probands without hormonally related VTE (IR 0.13 [95%
CI 0.05–0.27], HR 3.3 [95% CI 1.5–7.9]; P = 0.011).
When considering only relatives of female probands,
the noted heterogeneity with the higher HRs of pregnancy
and, to a lesser extent, COC use (Table 3) is mainly
observed in the relatives of female probands with a hor-
monally related VTE. The risk estimates in relatives of
female probands without hormonally related VTE were
substantially lower (Table 4). An overview of all crude
incidence rates is presented in the Table S1.
Discussion
In this large cohort study of first-degree female relatives of
thrombophilic patients with VTE, which evaluated possi-
ble sex- and hormone-specific aspects in family history,
the overall absolute risk of VTE was not significantly dif-
ferent between female relatives of male or female patients.
However, extended Cox regression analyses showed that
the contribution of pregnancy-postpartum to the risk of
VTE was almost double in female relatives of female
patients (HR 11.6) compared with female relatives of male
patients (HR 6.6), although not significant (P = 0.39).
When considering only relatives of female patients, the
noted heterogeneity in the contribution of pregnancy and
to a lesser extent COC use to the risk of VTE is mainly
observed in relatives of patients with a hormonally related
VTE. This difference is also reflected by the 3-fold higher
absolute risk in female relatives of female patients with
hormonally related VTE (HR 3.3, 95% CI 1.5–7.9;
P = 0.011). The observed heightened risks suggest that
female relatives of patients with hormonally related VTE
are more susceptible to hormone exposure.
Several studies have explored the impact of positive
family history and it is considered an independent risk
factor of VTE with reported odds ratios varying between
2.2 and 2.7 [4,12,13]. Additionally, two studies have
reported the VTE risk of a positive family history as
higher in female relatives during fertile age than in male
relatives of that age [14,15].












Probands*, n 179 286 195 91
Ever COC users, % NA 66.0 85.6 68.1
Ever pregnant, % NA 70.2 68.0 76.9
Ever pregnant + ever COC use % NA 56.1 56.0 56.2
Age (IQR) at time of VTE, yrs 46 (35–55) 32 (24–44) 27 (22–38) 44 (34–52)
Female relatives‡, n 401 604 394 206
Thrombophilia 179 (45) 306 (52) 198 (50) 70 (34)
Mild thrombophilic defects§, n (%) 111 (28) 209 (35) 113 (29) 48 (23)
Severe thrombophilic defects¶, n (%) 68 (17) 107 (18) 85 (22) 22 (11)
Total follow-up, yrs** 9.757 14.438 9.014 5.299
Ever COC users, n (%) 285 (71) 428 (71) 280 (71) 145 (70)
Total number of pill yrs 2173 3340 1941 1360
Duration of use 3.56 3.26 2.76 4.78
Ever pregnant, n (%) 283 (71) 407 (67) 258 (66) 145 (70)
Total number of pregnancy yrs 759 1073 687 378
Pregnancy time, yrs 2.0 2.0 1.9 2.0
Age (IQR) at time of VTE, yrs 28 (24–35) 26 (22–31) 26 (22–31) 26 (19–31)
VTE, n 38 46 39 7
Type of VTE
DVT 26 29 26 3
PE 8 10 6 4
DVT + PE 1 3 3 –
Other 3 4 4 –
VTE without hormone exposure 9 6 5 1
VTE during COC use 15 (40) 19 (41) 15 4
Duration COC use, yrs 4.0 0.46 5.3
VTE during pregnancy/postpartum 14 (37) 21 (46) 19 2
COC = combined oral contraceptive; NA = data not applicable; VTE = venous thromboembolism. Data are given as median unless otherwise indi-
cated. *Probands: patients with established VTE. †In one female proband information on exposure hormone exposure at time of VTE was
unknown; therefore, her four relatives (who experienced no VTE during follow-up) were excluded. ‡Relatives: first-degree relatives of the probands.
§Mild thrombophilic defects: factor V Leiden or prothrombin G20210A mutation. ¶Antithrombin, protein C, or protein S deficiency, including 47
(4.7%) women who were heterozygous for both factor V Leiden and prothrombin G20210A mutation and women who were homozygous for factor
V Leiden or prothrombin G20210A mutation. **Observation years in female relatives restricted to time between age 15 and 50 yrs.
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To our knowledge, only one study has evaluated sex of
patient as one of the potential predictors of VTE risk in
their first-degree relatives. The authors reported highest
VTE risk in relatives of patients with unprovoked VTE
and in relatives of patients who had VTE at younger age
(< 45 yrs), whereas sex of patient was no significant risk
indicator for VTE (odds ratio 0.96 [0.67–1.38]) [16]. How-
ever, in this study those patients with estrogen-associated
VTEs were classified as having unprovoked VTE. It is
well possible that the highest risk in relatives of young
patients with VTE (age < 45 yrs) as found in this study,
is partly explained by an increased risk in female relatives
of patients with hormonally (estrogen)-related VTEs (who
are inherently young), as observed in our study. In our
study, we also evaluated the influence of patient’s age at
time of first VTE and observed an overall increased risk
of VTE in female relatives of younger patients (first VTE
< 45 yrs), but in multivariable analyses, influence of
patient’s age was no longer an independent risk indicator.
Although the authors of this study by Couturaud et al.
[16] indicate that it is possible that inclusion of patients
with estrogen-associated VTE among the patients with
unprovoked VTE could have diluted the comparison of
VTE risk between first-degree relatives of patients with
unprovoked vs. provoked VTE, they were unable to
assess this directly. Thus, no previous studies with a simi-
lar objective are available for comparison.
Our study has its limitations as discussed previously in
the separate publications based on these family cohorts
[1–3,7,8]. Due to the study design, not all events were
established by objective techniques, because these were
not yet available at the time. Consequently, the reported
absolute risk of VTE may have been overestimated. Fur-
ther, we were not able to adjust for variables such as
BMI, trauma and surgery, as data on these ‘temporary’
risks were not complete for the whole exposure period.
Although we a priori defined subgroup analyses, the main
Table 2 Crude HRs with corresponding incidence rates and adjusted
HRs in female relatives of all probands











aged < 45 yrs vs.
probands aged
≥ 45 yrs at time of
first VTE*,‡


















COC use vs. no
COC use*,‡,§










HR= hazard ratio; IR = incidence rate. Mild thrombophilia: factor
V Leiden or prothrombin G20210A mutation. Severe thrombophilia:
antithrombin, protein C, or protein S deficiency, and double
heterozygous, or homozygous factor V Leiden or prothrombin
G20210A mutation. Probands: patients with established VTE. *Inci-
dence rates are presented in the Table S1. †Adjusted for clustering
within families. ‡Variables included in the initial univariable analysis.
§Variables included in the final multivariable analysis.
Table 3 Adjusted HRs of mild or severe thrombophilia, COC use,










3.2 (1.3–7.8) 3.4 (1.6–7.4)
Severe thrombophilia
vs. no thrombophilia‡
13.0 (5.2–32.6) 10.2 (4.4–23.7)
COC use vs. no COC use‡ 2.7 (1.5–5.0) 3.6 (1.8–7.1)
Pregnancy vs.
no pregnancy‡
6.6 (2.8–15.2) 11.6 (6.3–21.3)
HR = hazard ratio. Mild thrombophilia: factor V Leiden or pro-
thrombin G20210A mutation. Severe thrombophilia: antithrombin,
protein C, or protein S deficiency, and double heterozygous, or
homozygous factor V Leiden or prothrombin G20210A mutation.
Probands: patients with established VTE. *Incidence rates are pre-
sented in the Table S1. †Adjusted for clustering within families.
‡Variables included in the multivariable analysis.
Table 4 Adjusted HRs of mild or severe thrombophilia, COC use,
and pregnancy in female relatives of female probands with and with-
















3.7 (1.5–9.2) 1.5 (0.2–9.0)
Severe thrombophilia
vs. no thrombophilia‡
10.5 (3.9–28.0) 4.0 (0.4–43.0)
COC use vs. no
COC use‡
3.3 (1.6–7.1) 4.6 (1.0–21.5)
Pregnancy vs. no
pregnancy‡
12.2 (6.3–23.8) 7.3 (1.4–38.1)
HR = hazard ratio. Mild thrombophilia: factor V Leiden or pro-
thrombin G20210A mutation. Severe thrombophilia: antithrombin,
protein C, or protein S deficiency, and double heterozygous, or
homozygous factor V Leiden or prothrombin G20210A mutation.
Probands: patients with established VTE. *Incidence rates are pre-
sented in the Table S1. †Adjusted for clustering within families.
‡Variables included in the multivariable analysis.
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limitation is that results of our analyses are based on
small numbers of VTE. All included centers were univer-
sity hospitals, which could have led to a selection bias of
younger and more severe VTE cases. However, in our
cohorts, only the probands were referred to the university
hospitals. Compared with a Dutch population-based
cohort [17], our female probands were indeed younger,
but not the male probands (mean age 46 yrs in male and
35 yrs in female probands vs. 49 yrs in male and 43 yrs
female cases, respectively). The proportion of PE was not
higher than expected (21%). The first-degree relatives of
the probands were identified by pedigree analysis, so no
selection bias could not have occurred there.
Strong points of our pooled family cohort are the
inclusion of consecutive patients with symptomatic VTE
and the inclusion of their female relatives who all have
confirmed positive family history. Further, extensive
efforts made to minimize the recall bias on hormone
exposure resulted in an almost complete data collection
on exposure to hormone factors during reproductive age,
in both female relatives and patients. Moreover, due to
the cohort design, we were able to estimate the absolute
risk of VTE.
Conclusions
This is the first analysis taking into account a family his-
tory, based on a female patient with a hormonally related
VTE. Although further research is needed, our findings
suggest that a family history originating from a female
patient, that is, a mother or sister, especially when that
patient experienced a COC- or pregnancy-related VTE
may further increase VTE risk in her female relatives.
This information could be important in the counseling of
women on contraceptive options.
Addendum
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